Precision BioSciences, Inc.

Approximately 300 million people globally and more than 1 million people in the US are estimated to have chronic hepatitis B infection. An estimated 15% to 40% of patients with HBV infections may develop complications, such as cirrhosis, liver failure, or liver cancer, which account for the majority of HBV-related deaths. Since the mid-1990s, there has been minimal innovation in addressing this issue. At Precision Biosciences, we are committed to addressing this challenge by pioneering bold initiatives for the infected patient populations through revolutionary genome editing treatments. #WorldHepatitisDay #HepatitisBTreatment #GeneEditing #Biotech #DTIL

Have you heard? Precision BioSciences has been added to the Russell Microcap Index! The annual Russell US Indexes reconstitution captures the 4,000 largest US stocks as of Tuesday, April 30, ranking them by total market capitalization. Learn more: https://loom.ly/25F3f18 #GeneEditing #Biotech #DTIL

Have you heard? Precision BioSciences has been added to the Russell Microcap Index! The annual Russell US Indexes reconstitution captures the 4,000 largest US stocks as of Tuesday, April 30, ranking them by total market capitalization. Learn more: https://loom.ly/25F3f18 #GeneEditing #Biotech #DTIL

Are you free on July 15 at 12:30 pm ET (9:30 am PT)? Join Precision BioSciences for its presentation at the JonesTrading Healthcare Seaside Summit! Discover how we have distinguished ourselves as a cutting-edge gene editing company, leveraging our innovative proprietary ARCUS® platform to advance in vivo gene editing therapies. Register today! https://loom.ly/UwrhRSU *A live webcast of the presentation will also be accessible on Precision’s website in the Investors section under Events & Presentations at https://lnkd.in/epAiWMAa #GeneEditing #Biotech #DTIL

We're honored to have Wendy Shoop, PhD, represent the Precision team at the United Mitochondrial Disease Foundation’s (UMDF) Mitochondrial Medicine 2024 Conference! Wendy shared details from our lead PBGENE-PMM program targeting m.3243 mitochondrial disease and showcased the broader applicability of ARCUS to target other mitochondrial mutations. Given ARCUS’ ability to target the root cause of disease, we are excited by our data generated to date and are working diligently to advance PBGENE-PMM towards an Investigational New Drug and/or Clinical Trial Application in 2025. Learn more, https://loom.ly/f8wGqgY #GeneEditing #MitoMed24 #DTIL

World-class clinical investigators added to Precision’s Scientific Advisory Board as PBGENE-HBV Program Nears Clinical Readiness! As crucial milestones approach, Dr. Mark Sulkowski and Dr. Jordan Feld have joined Precision's Scientific Advisory Board alongside Dr. Raymond Schinazi, an esteemed trailblazer in hepatitis treatments. Together, their significant contributions to the field of hepatitis B solidify their positions as thought-leaders, and we are pleased to welcome advisors of such high caliber to our team. Meet our SAB Board 👉 https://loom.ly/SCKqqLs Read Precision's latest PR 👉 https://loom.ly/JGM0mXw #GeneEditing #Biotech #DTIL

Precision's Michael Amoroso, CEO; Jeff Smith, Co-Founder & CRO; and Alex Kelly, CFO, will attend and present at the Goldman Sachs 45th Annual Global Healthcare Conference on Wed, Jun 12th at 10 a.m. ET. Sign up today to join the webcast: tinyurl.com/4u8nt7nt #GeneEditing #Biotech #DTIL

Here's what the Precision team has been up to this week! ✅ Precision presented late-breaking data at the European Association for the Study of the Liver (EASL) in Milan. ✅ Precision released preclinical data highlighting PBGENE-HBV's ability to specifically cut HBV DNA leading to elimination of cccDNA and inactivation of integrated HBV DNA without impacting any sites in the human genome, including no editing-associated translocations in HBV infected primary human hepatocytes; PBGENE-HBV was well tolerated across multiple administrations with no off-target editing observed; preclinical safety data supports advancement of PBGENE-HBV to clinical trials as a potentially curative, finite treatment for chronic hepatitis B with IND and/or CTA on-track for submission in 2024. ✅ Precision's Emily Harrison, PhD, Senior Scientist - Hepatitis Research Leader, and Cassie Gorsuch, PhD, VP Gene Therapy, spoke at The HBV Forum in Milan about the Company's PBGENE-HBV program. The Company's work to date continues to highlight the potential of PBGENE-HBV as a curative treatment for chronic hepatitis B and further validates our ARCUS® platform to potentially deliver safe and efficacious in vivo gene editing therapies. Read our latest press release: https://loom.ly/ZFKBnGo #GeneEditing #Biotech #DTIL

The new preclinical safety data that we presented at EASL | The Home of Hepatology Congress for our clinical candidate, PBGENE-HBV, was featured in BioWorld. Current treatment options achieve viral suppression but do not eliminate cccDNA and inactivate integrated HBV DNA. Our in vivo gene editing therapy, PBGENE-HBV, offers a potential functional cure for chronic hepatitis B. Read more about our propriety approach & the treatment landscape of HBV here: https://bit.ly/3XgzjeV #EASL2024

Precision's Michael Amoroso, CEO; Jeff Smith, Co-Founder and CRO; and Alex Kelly, CFO, will participate as panelists at Jefferies Global Healthcare Conference on June 5 to discuss Precision's differentiated ARCUS gene editing platform and upcoming clinical stage programs moving towards execution in 2024-2025 with an audience of over 500 public & private healthcare companies, institutional and private equity investors, and VCs. Webcast registration available at, tinyurl.com/mv9hm6x8. #JefferiesHealthcare